The Endobronchial Ultrasound Biopsy Market was valued at USD 728.6 Million in 2024, and is projected to reach USD 966.9 Million by 2030, rising at a CAGR of 4.83%. This growth can be attributed to the increasing incidence of cancer, advancements in Endobronchial Ultrasound (EBUS) technology, a rising elderly population, a higher occurrence of respiratory diseases, and the growing acceptance of minimally invasive procedures. For instance, the World Health Organization (WHO) estimates that there will be more than 35 million new cancer cases in 2050, representing a 77% rise from the estimated 20 million cases recorded in 2022.
The endobronchial ultrasound biopsy market is also driven by advancements in medical technology and the increasing prevalence of respiratory diseases. EBUS devices are primarily used for diagnosing lung cancer, tuberculosis, and other respiratory disorders, offering a minimally invasive alternative to traditional surgical biopsies. Technological innovations such as high-resolution imaging, AI-assisted navigation, and improved probe designs have further enhanced the precision and efficiency of EBUS procedures. In addition, the shift toward personalized medicine and early detection strategies in oncology has enhanced demand for these devices, as they support targeted diagnostic interventions that improve patient outcomes.
Moreover, the market's growth is also fueled by demographic trends such as the growing geriatric population, which is more vulnerable to respiratory conditions such as COPD and asthma. For instance, according to the U.S. Census Bureau, around 57.88% of the country’s population was aged 65 years and above in 2023, accounting for 17.5% of the total population. This geriatric population share is further expected to increase over the forecast period. Furthermore, emerging economies are also witnessing market growth due to their large patient pools affected by air pollution-related respiratory disorders. For instance, countries such as China and India have seen increased adoption of EBUS devices due to high rates of lung cancer linked to poor air quality. Moreover, cost-effectiveness compared to invasive alternatives such as mediastinoscopy has made EBUS attractive for healthcare providers.
This product will be delivered within 1-3 business days.
The endobronchial ultrasound biopsy market is also driven by advancements in medical technology and the increasing prevalence of respiratory diseases. EBUS devices are primarily used for diagnosing lung cancer, tuberculosis, and other respiratory disorders, offering a minimally invasive alternative to traditional surgical biopsies. Technological innovations such as high-resolution imaging, AI-assisted navigation, and improved probe designs have further enhanced the precision and efficiency of EBUS procedures. In addition, the shift toward personalized medicine and early detection strategies in oncology has enhanced demand for these devices, as they support targeted diagnostic interventions that improve patient outcomes.
Moreover, the market's growth is also fueled by demographic trends such as the growing geriatric population, which is more vulnerable to respiratory conditions such as COPD and asthma. For instance, according to the U.S. Census Bureau, around 57.88% of the country’s population was aged 65 years and above in 2023, accounting for 17.5% of the total population. This geriatric population share is further expected to increase over the forecast period. Furthermore, emerging economies are also witnessing market growth due to their large patient pools affected by air pollution-related respiratory disorders. For instance, countries such as China and India have seen increased adoption of EBUS devices due to high rates of lung cancer linked to poor air quality. Moreover, cost-effectiveness compared to invasive alternatives such as mediastinoscopy has made EBUS attractive for healthcare providers.
Endobronchial Ultrasound Biopsy Market Report Highlights
- Based on product, the EBUS scopes segment dominated the market in 2024 with the largest revenue share of 33.0% owing to the demand for minimally invasive diagnostic procedures for lung cancer and mediastinal lymphadenopathy.
- Based on procedure, the EBUS-Transbronchial Needle Aspiration (EBUS-TBNA) segment accounted for the largest revenue share due to its higher diagnostic yield, reduced patient discomfort, and lower complication rates compared to conventional mediastinoscopy, which has increased their adoption among healthcare providers.
- Based on end-use, the hospitals segment dominated the market with the largest revenue share in 2024. This is attributed to the increasing adoption of EBUS biopsy in these healthcare facilities due to its high diagnostic accuracy and reduced patient risk compared to traditional biopsy methods.
- North America held the largest market share of over 29.18% in 2024. This can be attributed to the increasing prevalence of respiratory diseases, such as lung cancer, and the rising demand for minimally invasive diagnostic techniques.
Why Should You Buy This Report?
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Endobronchial Ultrasound Biopsy Market Variables, Trends & Scope
Chapter 4. Endobronchial Ultrasound Biopsy Market: Product Estimates & Trend Analysis
Chapter 5. Endobronchial Ultrasound Biopsy Market: Procedure Estimates & Trend Analysis
Chapter 6. Endobronchial Ultrasound Biopsy Market: End use Estimates & Trend Analysis
Chapter 7. Endobronchial Ultrasound Biopsy Market: Regional Estimates & Trend Analysis
Chapter 8. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
The companies profiled in this Endobronchial Ultrasound Biopsy market report include:- GE Healthcare
- Siemens Healthcare Private Limited
- Koninklijke Philips N.V.
- Boston Scientific Corporation
- Olympus Corporation
- Cook Group Incorporated
- FUJIFILM Holdings Corporation
- Medi-Globe Technologies GmbH
- ACE Medical Devices Pvt. Ltd.
- Praxis Medical
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 150 |
| Published | April 2025 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 728.6 Million |
| Forecasted Market Value ( USD | $ 966.9 Million |
| Compound Annual Growth Rate | 4.8% |
| Regions Covered | Global |
| No. of Companies Mentioned | 11 |
